Rabbit anti-thymocyte globulin administration to treat rejection in simultaneous pancreas and kidney transplant recipients with recent COVID-19 infection

Clin Transplant. 2021 Feb;35(2):e14149. doi: 10.1111/ctr.14149. Epub 2021 Jan 20.

Authors

Nicolas Barros¹, Asif A Sharfuddin², John Powelson³, Muhammad Yaqub², Oluwafisayo O Adebiyi², Cole Beeler¹, Andrew Lutz³, Jonathan A Fridell³

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
² Division of Nephrology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
³ Division of Transplantation, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.

PMID: 33179350
DOI: 10.1111/ctr.14149

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Animals
Antilymphocyte Serum / administration & dosage*
COVID-19 / epidemiology*
Comorbidity
Female
Graft Rejection / drug therapy*
Humans
Immunologic Factors / administration & dosage
Immunosuppressive Agents
Kidney Transplantation / adverse effects*
Male
Middle Aged
Pancreas Transplantation / adverse effects*
Pandemics
Rabbits
SARS-CoV-2
Transplant Recipients*

Substances

Antilymphocyte Serum
Immunologic Factors
Immunosuppressive Agents
thymoglobulin